Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.

Abstract

PURPOSE:

Histone deacetylase (HDAC) inhibitors are undergoing clinical evaluation in cancer therapy. Because HDAC modulation has been shown to enhance the radiosensitivity of tumor cells in vitro, we investigated the effects of the HDAC inhibitor MS-275 on the radioresponse of DU145 prostate carcinoma xenografts.

EXPERIMENTAL DESIGN:

As an indicator of HDAC inhibition in vivo, the histone acetylation status in tumor lysates was determined after two, four, and six injections of MS-275 delivered at 12-hour intervals, as well as 24 and 48 hours after the last injection. Tumor growth delay studies were then performed using this DU-145 xenograft model with radiation administered to leg tumors after the fourth dose of MS-275, which corresponded to the time of maximum histone hyperacetylation.

RESULTS:

An increase in histone hyperacetylation was detected in each tumor after two injections of MS-275 with a maximum hyperacetylation occurring after four to six injections. In tumor growth delay studies, the combination of MS-275 and radiation resulted in a greater than additive inhibition of tumor growth as compared with the individual modalities. As alternative sources for an indicator of drug radiosensitizing activity, histone hyperacetylation was determined in a series of normal tissues, including lymphocytes. Each of the normal tissues also had a maximal histone hyperacetylation after four to six injections of MS-275.

CONCLUSIONS:

These studies show that MS-275 enhances the radiosensitivity of DU145 xenografts and suggest that histone hyperacetylation status can serve as a useful marker for drug radiosensitizing activity.

• Authors: Kevin Camphausen, Tamalee Scott, Mary Sproull, Philip J Tofilon
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 10 Issue 18 Pt 1 Pg. 6066-71 (Sep 15 2004) ISSN: 1078-0432 [Print] United States
• PMID: 15447991 (Publication Type: Journal Article)

Chemical References

• Benzamides
• Biomarkers, Tumor
• Histone Deacetylase Inhibitors
• Histones
• Pyridines
• Radiation-Sensitizing Agents
• entinostat

Topics

• Acetylation
• Animals
• Benzamides (pharmacology)
• Biomarkers, Tumor
• Biopsy
• Cell Line, Tumor
• Cell Proliferation
• Histone Deacetylase Inhibitors
• Histones (metabolism)
• Humans
• Lymphocytes (metabolism)
• Male
• Mice
• Mice, Inbred C57BL
• Mice, SCID
• Neoplasm Transplantation
• Prostatic Neoplasms (metabolism)
• Pyridines (pharmacology)
• Radiation Tolerance
• Radiation-Sensitizing Agents (pharmacology)
• Time Factors